BUSINESS● LOW4d ago · Oct 30, 2026, 6:00 AM
A pharma giant is moving past one patent cliff — but another is already looming
CNBC · global
Disappointing data highlights Novartis' challenge to build its next generation of blockbuster medicines, following a series of clinical trial setbacks.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS16m agoProfitable banks but not enough credit: AFIS wants to solve the puzzle of private sector financingJeune AfriqueBUSINESS17m agoIcahn Enterprises declares $0.50 dividendSeeking Alpha Tech